Assessment of the timeliness of vaccination against pertussis in children of the first year of life and the reasons for the violation of the vaccination schedule

The maximum incidence of pertussis in young children confirms the importance of their timely immunization.

The goal is – to study the timeliness of vaccination against whooping cough, causes of violation of the vaccination schedule in young children, the effect of recombinant interferon-a on the post-vaccination period.

Materials and methods: the vaccination history and data on the course of the post-vaccination period after immunization with DPT and DaPT vaccines of 469 children at the age of 3–24 months were studied.

Results. The analysis showed that 14,9% of the observed children were not vaccinated against whooping cough in a timely manner. Of these: 34,3% had a written refusal to vaccinate (5.1% of the total number of observed children), in 32,8% of cases, the vaccination schedule was violated due to late arrival of parents, 32,9% of children by the start of immunization had medical challenges, and only half of them had justified contraindications. Non-serious side effects associated with immunization were observed in 11.3% of cases, statistically more often with DTP (22,0%) compared with DaPT (5.,5%). General and local reactions, in general, were recorded on DPT (6,9% and 15,1%, respectively) and less often developed with the use of DaPT (1,0% and 4,5%, respectively). Within 1 month after immunization, 16,2% of the observed children had an acute respiratory viral infection of varying severity. Those who did not receive antiviral therapy more often carried the disease in a moderate and severe form, which in all cases led to the postponement of the administration of the second and third doses of the vaccine.

Conclusion. To increase the timeliness of vaccination of children against whooping cough, medical professionals should persistently remind parents about the timing of turnout for the next vaccination, when making medical withdrawals, be guided by modern methodological documents and instructions for vaccines. The use of antiviral and immunomodulatory effects of IFN-alpha drugs allows us to comply with the recommended schedule for vaccination of children with a high risk of SARS in the post-vaccination period.

1. Pertussis. World Health Organization. https://www.who.int/health-topics/pertussis#tab=tab_1

2. Centers for Disease Control and Prevention. Pertussis in other countries. http://www.cdc.gov/pertussis/countries.html

3. Winter K., Glaser C., Watt J. et al. Pertussis Epidemic – California, 2014. Morb Mortal Wkly Rep 2014; 63: 1129–1132.

4. Yeung KH, Duclos P, Nelson EA, Hutubessy RC. An update of the global burden of pertussis in children younger than 5 years: a modelling study. Lancet Infect Dis. 2017;17(9): 974-980. doi: 10.1016/S1473-3099(17)30390-0

5. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2019 godu: Gosudarstvennyj doklad. – M.: Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebitelej i blagopoluchiya cheloveka, 2020.–299 s.

6. Lobzin YV, Babachenko IV, Shamsheva OV et al. Retrospective Study of the Clinical Epidemiological Characteristics of Pertussis in Infants Prior to Their First Vaccination in the Russian Federation. Infectious Diseases and Therapy. 2015; 4 (1): 113–123

7. Borgi A, Menif K, Belhadj S, Ghali N, Salmen L, Hamdi A, Khaldi A, Bouaffsoun A, Kechaou S, Kechrid A, Bouziri A. and Benjaballah N. Predictors of mortality in mechanically ventilated critical pertussis in a low Income country. Mediterr J Hematol Infect Dis. 2014; 6 (1): e2014059. doi: 10.4084/MJHID.2014.059.

8. Furuta М, Sin J, Ng ES, Wang K. Efficacy and safety of pertussis vaccination for pregnant women – a systematic review of randomised controlled trials and observational studies. BMC Pregnancy Childbirth. 2017; 17: 390. doi: 10.1186/s12884-017-1559-2

9. Barug D, Pronk I, van Houten MA, Versteegh FG, Knol MJ, van de Kassteele J, Berbers GA, Sanders E., Rots NY. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial. Lancet Infect Dis. 2019; 19: 392-401. doi: https://doi.org/10.1016/S1473-3099(18)30717-5

10. Wood N, Nolan T, Marshall H, Richmond P, Gibbs E, Perrett K, McIntyre P. Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial. JAMA Pediatr. 2018; 172: 1045-1052. doi:10.1001/jamapediatrics.2018.2349

11. Blain AE, Lewis M, Banerjee Е, Kudish К, Liko Ju, McGuire S, Selvage D, Watt J, Martin SW, Skoff TH. An Assessment of the Cocooning Strategy for Preventing Infant Pertussis—United States, 2011. Clin Infect Dis. 2016; 63(Suppl 4): S221–S226. doi: 10.1093/cid/ciw528

12. Rowe SL, Tay EL, Franklin LJ, Stephens N, Ware RS, Kaczmarek MC, Lester RA, Lambert SB. Effectiveness of parental cocooning as a vaccination strategy to prevent pertussis infection in infants: A case-control study. Vaccine. 2018 Apr 5;36(15):2012-2019. doi: 10.1016/j.vaccine.2018.02.094

13. Patterson J., Kagina B.M., Gold M., Hussey G.D., Muloiwa R. Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: A systematic review. Vaccine. 2018; 36 (40): 6007-6016. doi: https://doi.org/10.1016/j.vaccine.2018.08.022

14. Pertussis vaccines: WHO position paper – August 2015. Weekly Epidemiol Rec 2015; 90(35): 433-460. doi: 10.1016/j.vaccine.2015.10.136

15. Metodicheskie rekomendacii po vyyavleniyu, rassledovaniyu i profilaktike pobochnyh proyavlenij posle immunizacii. Moscow; 2019: 56.

16. Kharit S.M., Iosefovich O.V., Fridman I.V., Nacharova E.P., Tikhomirova K.K. Pertussis vaccination: problems, possible solutions. Journal Infectology. 2020;12(2):50-57. https://doi.org/10.22625/2072-6732-2020-12-2-50-57

17. Chernova Т.М., Timchenko V.N, Pogozheva O.S., Bezborodova O.A., Drozdetskaya Yu.I. Attitude of parents to extend of vaccination schedule: survey results. Pediatria n.a. G.N. Speransky. 2020; 99 (4): 158–166. doi: https://doi.org/10.24110/0031-403X-2020-99-4-158-166

18. Pis’mo Ministerstva zdravoohraneniya RF ot 23 avgusta 2017 g. N 15-2/10/2-5896 «O napravlenii metodicheskih rekomendacij “Protivopokazaniya k vakcinacii”»

19. Rikin S, Jia H, Vargas CY, et al. Assessment of temporally-related acute respiratory illness following influenza vaccination. Vaccine. 2018; 36:1958-1964. doi: 10.1016/j.vaccine.2018.02.105

20. Harit S.M., CHernyaeva T.V, Lakotkina E.A., Lobzin YU.V., Ujba V.V., Ruleva A.A., Drozdenko T.S., Fridman I.V., SHapovalov V.V. (pod red. akad. RAMN YU.V. Lobzina). Vakcinoprofilaktika: lekcii dlya prakticheskih vrachej. Sankt-Peterburg: NIIDI. 2012: 286 s.